Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYPRESS: Ad26.RSV.preF Vaccine for RSV in Older Adults
NCT03982199Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2019
- Primary completion
- Jun 2022
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Ad26.RSV.preF in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD) at 9 months. Started Aug 2019; status: terminated.
02
Drugs
Ad26.RSV.preF
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03982199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982199.